Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $18.00 Price Target at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective reduced by HC Wainwright from $27.00 to $18.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

ENTA has been the topic of several other research reports. Robert W. Baird decreased their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. JMP Securities reissued a “market outperform” rating and set a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock opened at $6.10 on Tuesday. Enanta Pharmaceuticals has a fifty-two week low of $5.70 and a fifty-two week high of $17.80. The firm’s fifty day moving average price is $9.64 and its 200-day moving average price is $11.66. The stock has a market cap of $129.28 million, a P/E ratio of -1.11 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The firm had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. During the same quarter in the previous year, the firm earned ($1.33) EPS. The business’s quarterly revenue was down 22.8% compared to the same quarter last year. On average, analysts predict that Enanta Pharmaceuticals will post -4.73 earnings per share for the current year.

Insider Transactions at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the sale, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 13.64% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC bought a new position in Enanta Pharmaceuticals in the 2nd quarter worth about $35,000. US Bancorp DE grew its holdings in shares of Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at approximately $122,000. Quest Partners LLC raised its holdings in Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 9,692 shares during the last quarter. Finally, Valence8 US LP purchased a new stake in Enanta Pharmaceuticals during the 3rd quarter valued at $207,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.